Glenmark Q1 FY27: Broad-based growth led by India and US respiratory

Consolidated revenue from operations was INR 40,185 million in Q1 FY27, up 23.1 percent year on year.

Q1 FY27 revenue was India INR 14,321 million, North America INR 10,974 million, Europe INR 7,472 million, and Emerging Markets INR 7,304 million.

Management cited respiratory launches, including first generic approval of fluticasone propionate 44 mcg (generic to FloVent HFA) with 180-day CGT exclusivity eligibility, plus multiple product launches and a fulvestrant injection relaunch.

RYALTRIS has been commercialized in 57 markets, with marketing applications submitted in more than 90 countries, and management cited global secondary sales growth upwards of 40 percent year on year in Q1 FY27.

Management stated R&D spend is expected to be around 7 percent to 8 percent of sales overall going forward.

Management said branded products are about 30 percent of Europe revenues currently and targeted to rise to about 60 percent over five years, with FY27 Europe growth expected at high single digit and a return to double-digit growth from next year.